BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Israel strikes Beirut amid rocket fire from Hezbollah and Iran - 2Toilet rats? Washington health officials warn of possible rodents in sewer systems after floods
- 3Pick Your Favored sort of cooking
- 4Newly identified species of Tanzanian tree toad leapfrog the tadpole stage and give birth to toadlets
- 5High velocity Internet services for Metropolitan Regions
- A few Exemplary Chinese Dishes, Which Are Famous Around the world
- 5 Wellbeing Applications Assist You With remaining Fit
- Most loved Caf\u00e9 Chain: Where Do You Get Your Caffeine Fix
- The Solution to Individual budget: Dominating Cash The board
- Ancient Egyptian pharaoh's boat is being reassembled in public at the Grand Egyptian Museum
- A definitive Manual for Well known Fragrances
- The Starbucks for Life game is back, along with your chance to win a 'Bearista' cold cup. Here's how to get your paws on one.
- Genome study reveals milestone in history of cat domestication
- Without evidence, CDC changes messaging on vaccines and autism
